Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pierre Fabre Continues Oncology R&D Push

Sep 25 2023

• By Kevin Grogan

Cancer — • Source: Shutterstock

Related Content

Scorpion Partners Two Assets With Pierre Fabre To Prioritize Investment In A Third

Apr 04 2023

Bye Bye Vernalis And Another Blow For UK Biotech

Aug 10 2018

Pierre Fabre Fights Off Rivals For Rights To Atara's Allogeneic T-Cell Therapy

Oct 08 2021

Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal

Jun 18 2019

A Master Of Firsts: Pascal Touchon On Atara Bio And The Maturing Cell Therapy Ecosystem

Jun 15 2023

Related Companies

Pierre Fabre

Vernalis (R&D) Ltd.

HitGen Inc.

Scorpion Therapeutics, Inc.

Array BioPharma, Inc.

Pfizer Inc.

Puma Biotechnology, Inc.

Atara Biotherapeutics, Inc.

Additional Topics

M & A Business Strategies Clinical Trials Research & Development Deals Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window